Join
Live feed
·
INSIDERFilingvia Quantisnow
Ovid Therapeutics Inc. logo

Chief Financial Officer Carter Charles Ross was granted 50,000 shares, increasing direct ownership by 113% to 94,375 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
OVID· Ovid Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track OVID (Ovid Therapeutics Inc.) and more on Quantisnow.